Sign In
Buy GTBP
$0.294
-0.0143 (-4.65%)
At Close: Jul 31, 2026
BEVERLY HILLS, Calif., May 12, 2021 /PRNewswire/ — GT Biopharma, Inc. (NASDAQ:… The post GT Biopharma Announces Update On The Commencement Of The GTB-3550 TriKE™ Monotherapy Phase 2 Clinical Tri
BEVERLY HILLS, Calif., May 12, 2021 /PRNewswire/ -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's pr
Former Penny Stocks To Watch Making New Highs In May 2021
12:37pm, Monday, 03'rd May 2021
Penny stocks are hot right now and these former low-priced names are reaching for new highs this month. The post Former Penny Stocks To Watch Making New Highs In May 2021 appeared first on Penny Stock
OXIS International Inc. (GTBP) Gains As Market Dips: What You Should Know
07:02pm, Wednesday, 28'th Apr 2021
In the latest trading session, OXIS International Inc. (GTBP) closed at $11.74, marking a +0.34% move from the previous day.
3 Penny Stocks To Watch As Biotech Surges In April 2021
01:50pm, Monday, 26'th Apr 2021
These biotech penny stocks have begun turning heads in April 2021 The post 3 Penny Stocks To Watch As Biotech Surges In April 2021 appeared first on Penny Stocks to Buy, Picks, News and Information |
GT Biopharma Announces the Appointments of Gregory Berk, M.D. to Chief Medical Officer and Jeffrey S.
07:00am, Monday, 26'th Apr 2021
BEVERLY HILLS, Calif., April 26, 2021 /PRNewswire/ -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's p
Hot Penny Stocks To Watch In April 2021 If Biotech Is A Focus
11:09am, Wednesday, 21'st Apr 2021
List Of Penny Stocks To Watch Right Now The post Hot Penny Stocks To Watch In April 2021 If Biotech Is A Focus appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
GT Biopharma Reports Fourth Quarter and Year End 2020 Results and Business Update
07:00am, Monday, 19'th Apr 2021
BEVERLY HILLS, Calif., April 19, 2021 /PRNewswire/ -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's
GT Biopharma Announces Enrollment Of Patient 10 in GTB-3550 TriKE™ Phase I/II Clinical Trial
08:00am, Thursday, 08'th Apr 2021
BEVERLY HILLS, Calif., April 8, 2021 /PRNewswire/ -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's pr
GT Biopharma's TriKE™ Interim Clinical Trial Results Presented At Innate Killer Summit 2021
07:00am, Monday, 29'th Mar 2021
BEVERLY HILLS, Calif., March 29, 2021 /PRNewswire/ -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's p
GT Biopharma's GTB-3550 Cuts Bone Marrow Blasts In High-Risk Patients With Hematological Malignancies
09:39am, Wednesday, 17'th Mar 2021
GT Biopharma Inc (NASDAQ: GTBP) has reported updated interim data from Phase 1/2 clinical trial, evaluating the Company's lead candidate, GTB-3550, in high-risk myelodysplastic syndromes (MDS) an
GTBP Stock Price Increases Over 3% Pre-Market: Why It Happened
08:12am, Wednesday, 17'th Mar 2021
The stock price of GT Biopharma, Inc. (NASDAQ: GTBP) has increased by over 3% pre-market. This is why it happened.
GT Biopharma Announces Updated Interim GTB-3550 Trike™ Clinical Trial Results
08:00am, Wednesday, 17'th Mar 2021
BEVERLY HILLS, Calif., March 17, 2021 /PRNewswire/ -- GT Biopharma, Inc. (NASDAQ: GTBP) a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's
GTBP Stock Price Increases Over 150% Pre-Market: Why It Happened
04:52am, Tuesday, 09'th Mar 2021
The stock price GT Biopharma Inc (NASDAQ: GTBP) increased by over 150% pre-market. This is why it happened.
BEVERLY HILLS, Calif, Dec. 21, 2020 /PRNewswire/ -- GT Biopharma, Inc. (OTCQB: GTBP) (GTBP.PA) an immuno-oncology company focused on innovative therapies based on the Company's proprietary NK cell eng
